ID: ALA5278638

Max Phase: Preclinical

Molecular Formula: C19H15N5O2

Molecular Weight: 345.36

Associated Items:

Representations

Canonical SMILES:  COc1cncc(NC(=O)c2ccnn3cc(-c4ccccc4)nc23)c1

Standard InChI:  InChI=1S/C19H15N5O2/c1-26-15-9-14(10-20-11-15)22-19(25)16-7-8-21-24-12-17(23-18(16)24)13-5-3-2-4-6-13/h2-12H,1H3,(H,22,25)

Standard InChI Key:  FSDWOHNRBITTOF-UHFFFAOYSA-N

Associated Targets(Human)

GSK3A Tclin Glycogen synthase kinase-3 alpha (3764 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 345.36Molecular Weight (Monoisotopic): 345.1226AlogP: 3.05#Rotatable Bonds: 4
Polar Surface Area: 81.41Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 4.01CX LogP: 2.40CX LogD: 2.40
Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.61Np Likeness Score: -1.92

References

1. Hartz RA, Ahuja VT, Sivaprakasam P, Xiao H, Krause CM, Clarke WJ, Kish K, Lewis H, Szapiel N, Ravirala R, Mutalik S, Nakmode D, Shah D, Burton CR, Macor JE, Dubowchik GM..  (2023)  Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors.,  66  (6): [PMID:36950863] [10.1021/acs.jmedchem.3c00133]

Source